Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Accumulated Expenses (2020 - 2023)

Historic Accumulated Expenses for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to $20.9 million.

  • Cullinan Therapeutics' Accumulated Expenses rose 5507.51% to $20.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $20.9 million, marking a year-over-year increase of 5507.51%. This contributed to the annual value of $14.1 million for FY2022, which is 6480.12% up from last year.
  • Latest data reveals that Cullinan Therapeutics reported Accumulated Expenses of $20.9 million as of Q3 2023, which was up 5507.51% from $15.5 million recorded in Q2 2023.
  • Cullinan Therapeutics' Accumulated Expenses' 5-year high stood at $20.9 million during Q3 2023, with a 5-year trough of $4.2 million in Q2 2021.
  • Its 4-year average for Accumulated Expenses is $11.2 million, with a median of $11.2 million in 2022.
  • Per our database at Business Quant, Cullinan Therapeutics' Accumulated Expenses skyrocketed by 18114.81% in 2022 and then surged by 3050.16% in 2023.
  • Over the past 4 years, Cullinan Therapeutics' Accumulated Expenses (Quarter) stood at $4.6 million in 2020, then soared by 84.81% to $8.6 million in 2021, then skyrocketed by 64.8% to $14.1 million in 2022, then soared by 48.19% to $20.9 million in 2023.
  • Its Accumulated Expenses was $20.9 million in Q3 2023, compared to $15.5 million in Q2 2023 and $18.4 million in Q1 2023.